Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments.
Electroporation (EP) has been used in basic research for the past 25 years to aid in the transfer of DNA into cells in vitro. EP in vivo enhances transfer of DNA vaccines and therapeutic plasmids to the skin, muscle, tumors, and other tissues resulting in high levels of expression, often with serological and clinical benefits. The recent interest in nonviral gene transfer as treatment options for a vast array of conditions has resulted in the refinement and optimization of EP technology. Current research has revealed that EP can be successfully used in many species, including humans. Clinical trials are currently under way. Herein, the transition of EP from basic science to clinical trials will be discussed.
Bodles-Brakhop
Angela M
AM
VGX Pharmaceuticals, Inc., 2700 Research Forest Drive, Suite 180, The Woodlands, Texas 77381, USA. rdraghia@vgxp.com
Heller
Richard
R
Draghia-Akli
Ruxandra
R
D000818:Animals; D018274:Electroporation / Q000379:methods*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D019444:Vaccines, DNA / Q000008:administration & dosage*
D019444:Vaccines, DNA